Beta-lactamase Producing Organisms

Introduction & Classification - Enzyme Undercover

Beta-lactamases: Bacterial enzymes. Hydrolyze $\beta$-lactam ring of antibiotics (penicillins, cephalosporins) $\rightarrow$ inactivation. Primary resistance mechanism.


• Mechanism: Cleave amide bond in $\beta$-lactam ring.
• Classification:
  • Ambler (Molecular): Protein sequence. Four classes (A, B, C, D).
    • A: Serine (e.g., TEM, SHV, CTX-M).
    • B: Metallo (MBLs), $Zn^{2+}$ needed. (e.g., NDM, VIM, IMP).
    • C: Serine (e.g., AmpC).
    • D: Serine (e.g., OXA).
  • Bush-Jacoby-Medeiros (Functional): Substrate/inhibitor. Three main groups.
    • Gp 1: Cephalosporinases (Ambler C).
    • Gp 2: Broad spectrum, clavulanate-inhibited (Ambler A, D).
    • Gp 3: MBLs, clavulanate-resistant (Ambler B).


⭐ Ambler Class B beta-lactamases (metallo-beta-lactamases) require zinc for activity and are not inhibited by clavulanic acid, sulbactam, or tazobactam.

Key Producers, ESBLs & AmpC - Resistance Spreaders

• Extended-Spectrum β-Lactamases (ESBLs)

  • Producers: Enterobacteriaceae (e.g., E. coli, K. pneumoniae, P. mirabilis).
  • Spectrum: Hydrolyze penicillins, 1st-3rd gen cephalosporins, aztreonam.
  • Inhibited by: Clavulanate, sulbactam, tazobactam.
  • Key Types: TEM, SHV, CTX-M.

  ⭐ CTX-M type ESBLs are the most prevalent worldwide, particularly in E. coli and Klebsiella pneumoniae.

• AmpC β-Lactamases

  • Origin: Chromosomal (inducible) or plasmid-mediated.
  • Producers: 📌 ESCAPPM group (Enterobacter, Serratia, Citrobacter, Acinetobacter, Proteus, Providencia, Morganella), P. aeruginosa.
  • Spectrum: Hydrolyze penicillins, all cephalosporins (incl. cephamycins), aztreonam.
  • NOT inhibited by: Clavulanate, sulbactam, tazobactam.

• Resistance Spread

  • Plasmids: Major vectors for horizontal gene transfer of ESBL & AmpC genes, enabling rapid dissemination.

Carbapenemases - Fortress Breakers

Hydrolyze most β-lactams, incl. carbapenems (imipenem, meropenem). Critical resistance threat globally. Key classes:

• Characteristics & Examples:
  • Class A (KPC, GES): Potent serine proteases. KPC in K. pneumoniae, plasmid-mediated.
  • Class B (NDM, VIM, IMP): MBLs (Metallo-β-lactamases), require $Zn^{2+}$ ions. NDM: broad resistance, rapid global spread (plasmids).
  • Class D (OXA-48 like): Serine proteases in Enterobacterales. Weaker hydrolysis, clinically significant with other resistance.
• Detection:
  • Phenotypic: Carba NP test, mCIM/eCIM. (Modified Hodge Test less used).
  • Molecular: PCR (gold standard for specific gene identification).
• Treatment Challenges:
  • Limited options. Newer: ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol. Older (colistin, tigecycline) have toxicity risks.

⭐ NDM-1 (New Delhi Metallo-beta-lactamase-1) confers resistance to nearly all beta-lactams, including carbapenems, and is often carried on mobile genetic elements, facilitating rapid spread.

Detection & Management - Clinical Counterstrike

Detection Pathway:

Therapeutic Strikes:

• ESBL: Carbapenems, Ceftazidime-avibactam (Caz-Avi), Piperacillin-tazobactam (use cautiously).
• AmpC: Cefepime, Carbapenems. (Avoid 3rd gen cephs if inducible).
• CRE: Caz-Avi (KPC, OXA-48), Meropenem-vaborbactam (KPC). Often combination therapy.

⭐ Ceftazidime-avibactam is active against KPC and OXA-48 producers, as well as ESBLs and AmpC, but not metallo-beta-lactamases.

High‑Yield Points - ⚡ Biggest Takeaways

• Beta-lactamases hydrolyze the beta-lactam ring, causing antibiotic inactivation.
• Key types: ESBLs, AmpC, and Carbapenemases (e.g., KPC, NDM-1, OXA-48).
• ESBLs: Resist penicillins, cephalosporins, aztreonam. Inhibited by clavulanate.
• AmpC: Often chromosomal, inducible. Resists beta-lactamase inhibitors. Found in SPACE organisms.
• Carbapenemases: Hydrolyze carbapenems. Confer multi-drug resistance. Examples: KPC, NDM-1.
• Detection: Phenotypic tests (DDST for ESBLs, MHT for carbapenemases) and molecular assays.
• Treatment: Carbapenems for ESBLs (if susceptible), newer combinations (e.g., ceftazidime-avibactam), colistin for CRE.